Insights

Adapting biopharma launches in the COVID-19 landscape

Ben Hohn and Judith Kulich


Read the article

With the sudden shift to minimize personal interaction and the refocusing of many hospitals on COVID-19, cross-functional launch teams must reconsider whether to launch, and if so, how to change their launch execution. In this Pharmaceutical Executive article, ZS experts Ben Hohn and Judith Kulich discuss how biopharma launches must adapt to new realities. Read the Pharmexec article.

About the Experts





Judith Kulich leads ZS’s pipeline and launch strategy practice and is a managing principal in the San Francisco office.





Ben Hohn is the East Coast region lead for ZS’s pipeline and launch strategy practice.

Contact ZS